LncRNA OLMALINC promotes osteosarcoma progression through USP1-mediated autophagy suppression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is an aggressive bone cancer with poor outcomes, especially in advanced stages.
• The molecular drivers of OS, particularly the regulation of autophagy, require further elucidation.
• Understanding novel regulatory pathways is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To identify novel molecular regulators of autophagy in osteosarcoma.
• To investigate the role of a newly discovered long non-coding RNA (lncRNA), OLMALINC, in OS progression.
• To explore the therapeutic potential of targeting the OLMALINC pathway.

Main Methods:

• Integrated analysis of single-cell and transcriptomic data to identify key regulatory lncRNAs.
• Functional studies involving manipulation of OLMALINC expression in OS cells.
• Transcriptome analysis and RNA immunoprecipitation to identify downstream targets.
• In vitro and in vivo experiments evaluating drug combinations.

Main Results:

• OLMALINC was identified as a significantly upregulated lncRNA in OS tissues, correlating with poor prognosis.
• Altering OLMALINC expression modulated OS cell progression and autophagy.
• OLMALINC directly targets Ubiquitin-Specific Peptidase 1 (USP1), forming an OLMALINC-USP1 axis.
• This axis inhibits autophagy and activates the hypoxia-inducible factor 1 (HIF-1α) pathway, promoting OS.
• Combination therapy with a USP1 inhibitor (ML-323) and doxorubicin showed synergistic anti-tumor effects.

Conclusions:

• A novel OLMALINC-USP1-HIF-1α axis promotes osteosarcoma progression by inhibiting autophagy.
• OLMALINC represents a potential therapeutic target for osteosarcoma.
• Combining USP1 inhibition with chemotherapy offers a promising strategy for improving osteosarcoma treatment outcomes.